Breaking News, Collaborations & Alliances

Lantern Pharma and Fox Chase Cancer Center Collaborate

Focus on advancing the development of LP-184 in pancreatic cancer.

By: Contract Pharma

Contract Pharma Staff

Lantern Pharma, a clinical-stage biopharma company using its proprietary RADR AI platform to improve drug discovery & development and identify patients who will benefit from its targeted oncology therapeutics, has announced a collaboration and research agreement with Fox Chase Cancer Center for the further development of Lantern’s LP-184 in pancreatic cancer. Based in Philadelphia, Fox Chase is a research center for pancreatic cancers and one of the four original cancer centers to rece...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters